Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/

Filter By:
Search by Keyword:

Displaying 21 - 30 of 216

Karen Winkfield named a fellow of the American Society for Radiation Oncology

Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, has been named a fellow of the American Society for Radiation Oncology.

https://news.vumc.org/2023/08/01/karen-winkfield-named-a-fellow-of-the-american-society-for-radiation-oncology/

Tue, 08/01/2023 - 12:00

Cancer_Health_Outcomes_and_Control_Research_Program

Tom Wilemon

Locked

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer.

https://news.vumc.org/2023/09/12/study-finds-new-genetic-susceptibilities-for-colon-cancer/

Tue, 09/12/2023 - 12:00

Cancer_Epidemiology_Research_Program

Tom Wilemon

Locked

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.

Disease Sites: Not Available

Phase: II

Investigator: Not Available

NCTID: NCT04197687

Protocol No: VICCBRE2241

Learn More

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Multiple Cancer Types

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Disease Sites: Gynecologic, Ovarian

Phase: III

Investigator: Crispens, Marta

NCTID: NCT06580314

Protocol No: NRGGYNGY036

Learn More

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Multiple Cancer Types

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.

Disease Sites: Colon, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Liver, Pancreatic, Rectal

Phase: I/II

Investigator: Keedy, Vicki

NCTID: NCT06630234

Protocol No: VICC-DTSAR24137P

Learn More

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Head/Neck

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Disease Sites: Head/Neck

Phase: II

Investigator: Rosenthal, Eben

NCTID: NCT04511078

Protocol No: VICCHN21109

Learn More

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Multiple Cancer Types

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Disease Sites: Breast, Gastrointestinal, Gynecologic, Head/Neck, Lung, Melanoma, Neuro-Oncology, Sarcoma, Urologic

Phase: II

Investigator: Choe, Jennifer

NCTID: NCT05564377

Protocol No: VICC-NTMDT23238

Learn More

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Multiple Cancer Types

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Disease Sites: Colon, Rectal

Phase: II/III

Investigator: Ciombor, Kristen

NCTID: NCT05174169

Protocol No: SWOGGI008

Learn More

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Multiple Cancer Types

This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Eltanexor works by trapping "tumor suppressing proteins" within the cell, thus causing the cancer cells to die or stop growing. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving eltanexor together with venetoclax may be safe, tolerable and/or effective in treating patients with relapsed or refractory MDS or AML.

Disease Sites: Leukemia, Myelodysplastic Syndrome, Phase I

Phase: I

Investigator: Ball, Somedeb

NCTID: NCT06399640

Protocol No: VICC-VCHEM23008P

Learn More